|MDACC Study No:||2010-0733 (clinicaltrials.gov NCT No: NCT01301807)|
|Title:||Phase 1/1b Study of the efficacy and safety of the combination of Panobinostat + Carfilzomib in patients with relapsed/refractory myeloma|
|Principal Investigator:||Jatin J. Shah|
|Treatment Agent:||Carfilzomib; Panobinostat|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
levels of carfilzomib and LBH589 (panobinostat) that can be given in
combination to patients with myeloma. The safety of this drug combination will
also be studied.